Rare diseases often face unique obstacles such as small patient populations, sensitive clinical profiles, and complex regulatory pathways. Certara integrates model-informed drug development (MIDD) strategies to address these complexities. 依托定量模型、监管专长及真实世界数据，我们赋能合作伙伴加速创新疗法开发，同时满足严苛监管要求。
罕见病和孤儿病
独特的挑战需要独特的方法
Partner with Certara to accelerate rare disease drug development
Advancing breakthroughs
in rare disease drug development
Accelerated approvals
Certara’s modeling and simulation strategies have led to expedited approvals, including rare and neglected diseases achieving accelerated pathways.
Expert regulatory guidance
With over 200 regulatory experts, Certara ensures seamless rare and neglected disease filings and compliance with global standards.
Quantifying small populations
Our clinical pharmacology expertise enables insights into biomarkers, endpoints, and exposure-response models from limited patient data.
市场准入解决方案
We employ robust frameworks to justify pricing, reimbursement, and access strategies for rare disease therapies.
Certara’s proven leadership in Rare Disease innovation
Certara combines cutting-edge biosimulation technology with decades of expertise to deliver impactful solutions for rare disease drug development.
Explore Certara’s Rare Disease solutions
Early development solutions
以终为始。
定量药理学服务
Quantitative modeling for informed decisions.
法规事务咨询
Comprehensive regulatory strategy and support.
Clinical pharmacology & translational medicine
Expertise in exposure-response models.
市场准入和定价
Robust frameworks for reimbursement success.
CMC services
Early development manufacturing strategies.
DMPK solutions
Advance your compounds from candidate selection to clinical development.
Nonclinical development services
Preclinical insights for rare diseases.
Early HTA engagement
Proactive health technology assessments.
药物研发管理
End-to-end program management.
PK/PD data programming support
Data-driven pharmacokinetics insights.
Real-world evidence
Leverage patient data for actionable insights.
Innovative solutions for rare diseases
查看全部Collaborate with Certara’s experts
Transform your rare disease drug development with Certara’s integrated solutions. From preclinical insights to market access strategies, we provide unparalleled expertise to guide you through every stage of the drug development process.
Comprehensive services: End-to-end support for rare disease programs.
Global leadership: Trusted by leading pharma and biotech companies.
Connect with us
Certara’s comprehensive drug development solutions
Frequently asked questions about rare disease drug development
What makes rare disease drug development challenging?
Small patient populations, sensitive profiles, and complex regulations create unique hurdles. Certara addresses these with advanced biosimulation and regulatory expertise.
How does Certara ensure regulatory success?
With over 200 experts, we provide proactive support from pre-IND to postmarketing stages, ensuring compliance and success.
Why is modeling and simulation critical in rare disease research?
M&S enables precise insights into small patient populations, biomarkers, and endpoints, improving trial outcomes and accelerating approvals.
